Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 44,297 shares, a decrease of 36.7% from the November 30th total of 69,969 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily trading volume, of 68,762 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 68,762 shares, the short-interest ratio is presently 0.6 days. Approximately 2.3% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Alaunos Therapeutics Price Performance

NASDAQ:TCRT traded down $0.01 during trading hours on Tuesday, reaching $3.44. 9,165 shares of the company were exchanged, compared to its average volume of 276,320. The firm has a market cap of $7.97 million, a price-to-earnings ratio of -1.49 and a beta of -1.29. The stock has a 50 day simple moving average of $3.27 and a 200 day simple moving average of $3.15. Alaunos Therapeutics has a 52-week low of $1.31 and a 52-week high of $6.20.

Alaunos Therapeutics (NASDAQ:TCRT) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($4.90) by $4.35.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.